FN2 Earnings Intelligence
Medpace Holdings, Inc. income statement
Medpace Holdings, Inc. (MEDP) Income Statement (annual) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - |
| - Cash | $461.3 | $28.3 | $245.4 | $669.4 | $497 |
| + Debt | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - |
| Revenue | $1,142.4 | $1,460 | $1,885.8 | $2,109.1 | $2,530.2 |
| % Growth | 23.4% | 27.8% | 29.2% | 11.8% | 20.0% |
| Gross Profit | - | - | - | - | - |
| % Margin | - | - | - | - | - |
| EBITDA | $214.6 | $297.7 | $361 | $474.7 | $562.1 |
| % Margin | 18.8% | 20.4% | 19.1% | 22.5% | 22.2% |
| Net Income | $181.8 | $245.4 | $282.8 | $404.4 | $451.1 |
| % Margin | 15.9% | 16.8% | 15.0% | 19.2% | 17.8% |
| Diluted EPS | $4.81 | $7.28 | $8.88 | $12.63 | $15.28 |
| % Growth | 25.3% | 51.4% | 22.0% | 42.2% | 21.0% |
| Operating Cash Flow | $263.3 | $388 | $433.4 | $608.8 | $713.2 |
| CapEx | $28.3 | $36.9 | $36.6 | $36.5 | $31.4 |
| Free Cash Flow | $235.1 | $351.2 | $396.7 | $572.3 | $681.9 |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue | $1,142.4 | $1,460 | $1,885.8 | $2,109.1 | $2,530.2 |
| Gross Profit | - | - | - | - | - |
| EBITDA | $214.6 | $297.7 | $361 | $474.7 | $562.1 |
| Net Income | $181.8 | $245.4 | $282.8 | $404.4 | $451.1 |
| Diluted EPS | $4.81 | $7.28 | $8.88 | $12.63 | $15.28 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $461.3 | $28.3 | $245.4 | $669.4 | $497 |
| Short-term Debt | - | $50 | $0 | - | - |
| Long-term Debt | - | - | - | - | - |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $263.3 | $388 | $433.4 | $608.8 | $713.2 |
| Capital Expenditure | $28.3 | $36.9 | $36.6 | $36.5 | $31.4 |
| Free Cash Flow | $235.1 | $351.2 | $396.7 | $572.3 | $681.9 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 23.4% | 27.8% | 29.2% | 11.8% | 20.0% |
| Gross Margin | - | - | - | - | - |
| EBITDA Margin | 18.8% | 20.4% | 19.1% | 22.5% | 22.2% |
| Net Margin | 15.9% | 16.8% | 15.0% | 19.2% | 17.8% |
| FCF Margin | 20.6% | 24.1% | 21.0% | 27.1% | 26.9% |
| Diluted EPS Growth | 25.3% | 51.4% | 22.0% | 42.2% | 21.0% |
Get the MEDP recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.